Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOTA-P-CARDIA Trial: Sotagliflozin in HFpEF Patients Without Diabetes
NCT05562063Phase 4Completed
- Start
- Oct 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Sotagliflozin with Placebo (2 arms). Primary endpoint: Left Ventricular Mass at 6 months. Started Oct 2022; status: completed.
02
Drugs
sotagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05562063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05562063.